Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $152
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.
Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price target from $137 to $152.